Home›Lopinavir›Lopinavir + Rifabutin

Does Lopinavir Interact with Rifabutin?

CDI records a contraindicated classification for Lopinavir and Rifabutin. The stored summary is: Lopinavir/ ritonavir 400/100 mg twice a day for 20 days 150 mg once a day for 10 days Healthy subjects (14) ↑ AUC by 203% c ↓ C max by 112% Reduce rifabutin dose by at least 75% (to a maximum 150 mg every other day or three times per week) when given with lopinavir/ritonavir combination. Co-administration of rifabutin with cabotegravir/rilpivirine prolonged-release injectable suspension is contraindicated Ritonavir 500 mg twice a day for 10 days 150 mg once a day for 16 days Healthy subjects (5) ↑ AUC by 300%, ↑ C max by 150% ND Reduce rifabutin dose by at least 75% (to a maximum 150 mg every other day or three times per week) when given with lopinavir/ritonavir combination. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Severity: Contraindicated
Rifabutin Class: Rifamycin Antimycobacterial
Management: Do not take together
Data Source: U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Lopinavir and your doctor is considering prescribing Rifabutin (or vice versa), make sure to:

Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
Ask whether the benefits of combining these medications outweigh the risks for your specific situation
Ask what symptoms to watch for that would indicate the interaction is causing problems
Ask about alternative medications that do not interact with your current regimen
Ask how frequently you should be monitored while these are co-prescribed
Never stop or change either medication without first consulting your healthcare provider

💊 Lopinavir(Kaletra)+💊 Rifabutin(Talicia)

Severity & Interaction Details

⛔

contraindicated

Avoid this combination

CDI classifies this record as contraindicated. Confirm the applicable product labeling with your prescriber or pharmacist.

Severity scale

MinorContra

On record

Yes

Drug A class

—

Drug B class

Rifamycin Antimycobacterial

Source

FDA drug label - rifabutin

What this means in plain English

Lopinavir/ ritonavir 400/100 mg twice a day for 20 days 150 mg once a day for 10 days Healthy subjects (14) ↑ AUC by 203% c ↓ C max by 112% Reduce rifabutin dose by at least 75% (to a maximum 150 mg every other day or three times per week) when given with lopinavir/ritonavir combination. Co-administration of rifabutin with cabotegravir/rilpivirine prolonged-release injectable suspension is contraindicated Ritonavir 500 mg twice a day for 10 days 150 mg once a day for 16 days Healthy subjects (5) ↑ AUC by 300%, ↑ C max by 150% ND Reduce rifabutin dose by at least 75% (to a maximum 150 mg every other day or three times per week) when given with lopinavir/ritonavir combination.

About Lopinavir and Rifabutin

Rifabutin is a Rifamycin Antimycobacterial. You may recognize them by the brand names Kaletra and Talicia.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: FDA drug label - rifabutin

Share this result:

WhatsApp Text / SMS Email

Also share on:X Facebook

Add more drugs

Check Lopinavir and Rifabutin against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.